Developing a universal vaccine to protect against various strains of influenza
Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model
This study is working on a new flu vaccine that could protect against many different strains of the virus, especially during pandemics, by boosting your immune response, and it will be tested in monkeys to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Osivax Sas NIH-funded |
| Lab location | 1 site (Paris, France) |
| Project ID | NIH-10935950 on NIH RePORTER |
What this research studies
This research aims to create a universal influenza vaccine that can provide broad protection against multiple strains of the virus. It focuses on targeting a highly conserved protein called nucleoprotein (NP) to stimulate a strong immune response, particularly through T-cells. By using a novel technology to enhance the vaccine's effectiveness, the researchers hope to reduce the risk of severe illness and death from influenza, especially during pandemics. The study will involve testing this vaccine approach in a non-human primate model to evaluate its efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for influenza complications, such as the elderly, immunocompromised individuals, and healthcare workers.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with current seasonal vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that offers long-lasting protection against various influenza strains, potentially saving millions of lives during pandemics.
How similar studies have performed: Other research has shown promise in developing universal vaccines targeting conserved viral proteins, indicating potential for success with this novel approach.
Where this research is happening
Paris, France
- Osivax Sas — Paris, France (Active)
Researchers
- Principal investigator: Nicolas, Florence — Osivax Sas
- Study coordinator: Nicolas, Florence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.